Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84108, USA.
Drug and alcohol dependence (Impact Factor: 3.6). 04/2011; 118(2-3):479-83. DOI: 10.1016/j.drugalcdep.2011.03.024
Source: PubMed

ABSTRACT Gender differences are known to occur in the pharmacokinetics of many drugs. Mechanisms may include differences in body composition, body weight, cardiac output, hormonal status, and use of different co-medications. Recently subtle gender-dependent differences in cytochrome P450 (CYP) 3A-dependent metabolism have been demonstrated. Buprenorphine N-dealkylation to norbuprenorphine is primarily performed by CYP3A. We therefore asked whether gender-dependent differences occur in the pharmacokinetics of buprenorphine.
A retrospective examination was made of control (buprenorphine/naloxone-only) sessions from a number of drug interaction studies between buprenorphine and antiretroviral drugs. Twenty males and eleven females were identified who had a negative cocaine urine test prior to participation in the control session and were all on the same maintenance dose (16/4 mg) of sublingual buprenorphine/naloxone. Pharmacokinetic data from their control sessions (buprenorphine/naloxone only) were sorted by gender and compared using the two-sample t-test.
Females had significantly higher area under the plasma concentration curve (AUC) and maximum plasma concentrations for buprenorphine, norbuprenorphine and norbuprenorphine-3-glucuronide. AUCs relative to dose per body weight and surface area were significantly higher for only norbuprenorphine. AUCs relative to lean body mass were, however, not significantly different.
Gender-related differences exist in the pharmacokinetics of buprenorphine; differences in body composition appear to have a major impact; differences in CYPA-dependent metabolism may also contribute.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Buprenorphine is largely prescribed for maintenance treatment in opioid dependence due to its safety profile. Nevertheless, fatalities at therapeutic dose have been described when associated with other central nervous system depressants, such as ethanol or benzodiazepines. Here, we report a case of death due to association of buprenorphine at therapeutic dose with benzodiazepines and ethanol. Although toxicity has been often attributed to its metabolite norbuprenorphine rather than to buprenorphine itself, in our case, norbuprenorphine was not detected in urine and bile and only in traces in blood. Moreover, the presence in blood of free buprenorphine but not of glucuronide metabolites argues for an unusual early death, at the beginning of buprenorphine metabolism. We propose that in the context of prior toxic impregnation, buprenorphine directly (and not via its metabolite norbuprenorphine) acted as a triggering factor by blocking the ventilatory response, rapidly leading to fatal respiratory depression.
    Journal of Forensic Sciences 10/2014; · 1.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Geschlechtsspezifische Unterschiede können einen relevanten Einfluss auf Auftreten und Behandlungsergebnisse bei akuten und chronischen Schmerzen haben. Männliche und weibliche Patienten sind unterschiedlich häufig von spezifischen Schmerzerkrankungen betroffen. Die Ursachen hierfür sind vielfältig und in genetischen Faktoren, hormonellen Effekten und anderen anatomischen und physiologischen Gegebenheiten zu finden. Unterschiedliche Prävalenzen für psychische Komorbiditäten (z. B. Depressive Störungen) und psychosoziale Faktoren, wie Rollenverhalten oder Strategien zum Umgang mit Schmerzen spielen eine wichtige Rolle. Außerdem wurden Unterschiede bei erwünschten und unerwünschten Medikamentenwirkung, sowie bei nichtmedikamentösen Therapieverfahren nachgewiesen. In Zeiten individualisierter Medizin ist es sinnvoll, die Einflüsse von Geschlecht, Alter und Ethnie weiter zu untersuchen. In diesem Beitrag werden die bisher bekannten Unterschiede vorgestellt und mögliche Ursachen diskutiert.
    Der Schmerz 01/2013; 27(5). · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Opioid maintenance therapy is a well-established first-line treatment approach in opioid dependence. Buprenorphine, a partial opioid agonist, has been found by numerous studies to be an effective and safe medication in the treatment of opioid dependence. At present, buprenorphine is available as a monodrug or in a fixed 4:1 ratio combination with naloxone. A diminished risk of diversion and abuse for the buprenorphine-naloxone combination is likely but not firmly established. Conventional formulations are given sublingually to avoid the hepatic first-pass effect. A novel film tablet is available only in the US and Australia. Other novel, sustained-release formulations (implant, depot) are currently being developed and tested. Recent studies, including a Cochrane meta-analysis, suggest that the retention with buprenorphine is lower than for methadone, but that buprenorphine may be associated with less drug use. Higher doses of buprenorphine are associated with better retention rates. Buprenorphine has a ceiling effect at the opioid receptor with regard to respiratory depression, and may cause fewer fatal intoxications than methadone. Possible antidepressant effects of buprenorphine and its use in comorbid psychiatric patients has not been studied in much detail. Clinical implications are discussed.
    Substance abuse and rehabilitation. 01/2015; 6:1-14.

Full-text (2 Sources)

Available from
May 21, 2014